INNOVANCE reagents support management of COVID-19 patients
Siemens Healthineers’s INNOVANCE assays help improve efficiencies, workflow and resource management following a COVID-19 diagnosis.
In hospitalised COVID-19 patients, elevated D-dimer levels have been found to be strongly associated with disease severity and even mortality reflecting the procoagulant status and high thrombotic risk observed in many COVID-19 patients. Therefore, the monitoring of D-dimer levels is recommended for hospitalised COVID-19 patients to stratify their thrombotic risk including testing for deep vein thrombosis and pulmonary embolism and guiding treatment over the course of the disease.
Treating COVID-19 patients with anticoagulants has been associated with improved outcomes, both in and out of the intensive care unit setting.
Accurate antithrombin measurement in COVID-19 patients undergoing anticoagulant treatment may be useful to determine the efficacy of anticoagulant therapy as antithrombin levels might be reduced.
Siemens Healthineers has a comprehensive portfolio of assays for detection and monitoring of coagulation disorders.
For more information, visit: https://www.siemenshealthineers.com/hemostasis/ innovance-reagents-for-coagulation-disorders
Supplier: Siemens Healthineers
Website:
